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Abstract The anti-proliferative, cytotoxic and apopto-
genic activities of delisheng, a Chinese medicinal
compound, has been investigated. In this study, the hepato-
carcinoma cell line (HepG2) and the liver cell line (L-02)
were exposed to delisheng (6.25, 50 and 100 ll/ml).
Delisheng suppressed the proliferation and viability of
normal liver L-02 cells slightly, but strongly inhibited the
proliferation and viability of hepatocarcinoma HepG2
cells. The ﬂow cytometric analysis of HepG2 cells dem-
onstrated that delisheng primarily arrested the HepG2 cells
at the G1 phase of the cell cycle. Annexin V-FITC/PI
staining corroborates the apoptogenic nature of delisheng
on HepG2 cells. The anti-proliferative and pro-apoptotic
effect of delisheng in HepG2 cells was associated with
changes in the Bcl-2/Bax ratio and the induction of
caspase-mediated apoptosis. Upregulation of DR5 expres-
sion was observed in HepG2 cells after treatment with
delisheng. The ﬁndings from the present study suggest that
delisheng has selective cytotoxic activities against HepG2
cells. Delisheng triggered time- and dose-dependent
apoptosis in HepG2 cells by activating the mitochondria-
mediated and death receptor-mediated apoptotic pathways.
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Introduction
Cancer is a complex multifactorial disease of the cell.
Transformed cells are not constrained by growth controls,
which regulate the proliferation of normal cells. Nowa-
days, chemotherapy is one of the most important and
key tools for cancer treatment. However, the effects of
such chemotherapeutic drugs on most solid tumors are
disappointing.
Hepatocellular carcinoma (HCC) is a highly malignant
tumor with very high morbidity and mortality rates, and a
poor prognosis. Despite extensive efforts by many inves-
tigators, systemic chemotherapy for HCC has been quite
ineffective, as demonstrated by low response rates and no
survival beneﬁts [1–4]. In recent years, it has been proven
that some traditional Chinese medicines (TCMs) have a
marked effect on treating HCC, with unique advantages,
and have gained wide acceptance as a safe, palliative and
effective treatment in China [5–9]. Delisheng (DLS), a
Chinese medicinal compound that is composed of ginseng,
milk vetch root, bufonis secretions and cantharidium, is
usually used alone or in combination with chemotherapy
for HCC and other cancers. Bufonis secretions, such as
bufalin, were found to generally inhibit growth of human
leukemia cells and were later examined in detail against the
liver carcinoma PLC/PRF/5 cell line [10]. Bufalin was also
found to inhibit endothelial cell proliferation and angio-
genesis and has effects on the proliferation of prostate
cancer cells [11, 12]. In vivo, Bufalin has signiﬁcant anti-
tumor activities in an orthotopic transplantation tumor
model of human hepatocellular carcinoma in nude mice
with no marked toxicity and was able to induce apoptosis
of transplanted tumor cells [13]. Chinese clinical research
reports that DLS injection removes blood stagnation and
has the effect of strengthening the body’s immunity. When
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10 days a month can alleviate speciﬁc symptoms such as
weakness, improve quality of life, extend life expectancy,
and lower prostate speciﬁc antigen (PSA) levels in 80% of
the prostate cancer patients [14]. Though DLS is attractive
as a natural product for medicinal use, its method of action
remains unclear.
Apoptosis, or programmed cell death, is thought to play
a key role in the development and regulation of growth of
both normal and cancerous cells. Induction of apoptosis has
been considered the major cytotoxic mechanism of anti-
cancer therapies. Generally, apoptosis may occur via the
mitochondrial (intrinsic) pathway [15] or the death receptor
(extrinsic) pathway [16]. In the mitochondrial (intrinsic)
pathway, the regulation of apoptosis involves a large set of
proteins including Bcl-2, an anti-apoptotic protein [17],
which disrupts the mitochondria membrane potential,
resulting in release of apoptogenic factors from the mito-
chondria to the cytoplasm.
To further understand the molecular mechanism of the
anti-tumor effects of DLS, we investigated the effects of
DLS in human hepatocarcinoma cells and normal liver
cells by using HepG2 and L-02 cell lines, respectively. We
found that DLS induces apoptosis in HepG2 cells and that
both extrinsic and intrinsic signaling pathways contributed
to DLS-induced apoptosis.
Materials and methods
Human cells and culture
Human cancer cells (HepG2) and normal liver cells (L-02)
were cultured in RPMI 1640 and DMEM medium, respec-
tively. Both RPMI 1640 and DMEM media were supple-
mented with 10% fetal bovine serum (heat inactivated),
penicillin (100 units/ml) and streptomycin (100 mg/ml).
Cell lines were maintained in a humidiﬁed incubator with
5% CO2 and 95% oxygen at 37C. Cells were passaged
twice a week at an initial density of 1 9 10
6 cells/ml.
MTT assay
MTT assay was done according to Kawada et al. 150 llo f
HepG2 cells (1 9 10
5 cells) suspended in RPMI 1640
medium supplemented with 10% fetal calf serum were
added to each well of a 96-well microtiter plate. Cells were
cultured in the presence or absence of delisheng (6.25, 25
and 100 ll/ml). Plates were incubated at 37 in a humidi-
ﬁed 5% CO2 incubator for 48 h. Then, 20 ll of MTT
(5 mg/ml) was added to each well and allowed to incubate
at 37C in a humidiﬁed 5% CO2 incubator for 4 h. Next,
150 ll DMSO was added to each well to dissolve the
formazan crystal that formed. The OD was recorded at
490 nm. The rate of growth inhibition (%) was expressed
as = (1-OD of treated/OD of control) 9 100%.
Cell cycle analysis
For the analysis of cell cycle phase distribution, respective
control and delisheng treated cancer cells (1 9 10
6 cells
per group) were washed with PBS after 24 h of delisheng
(25 ll/ml) and were ﬁxed in 70% ethanol and stained with
10 ll of propidium iodide (100 lg/ml) and 10 ll RNaseA
(5 lg/ml). DNA content of cells was subsequently ana-
lyzed by ﬂow cytometry (Becton–Dickinson, USA). Raw
data for the distribution of DNA content were expressed as
the percentage of G1, S, and G2 populations.
Annexin V-FITC/PI stained ﬂuorescence-activated cell
sorting (FACS)
Cells were harvested by trypsinization and washed twice
with cold PBS. The cells were centrifuged at 1,000 rpm for
5 min. The supernatant was discarded and the pellet was
resuspended in binding buffer at a density of 1.0 9 10
5–
1.0 9 l0
6 cells per ml. Then, 100 ll of the sample solution
was transferred to a 5 ml culture tube, and incubated with
5 ul of FITC-conjugated Annexin V and 5 ll of PI for
15 min at room temperature in the dark. Next, 400 llo f
binding buffer was added to each sample. The samples
were subsequently analyzed by FACS using Cell Quest
Research Software.
Immunocytochemistry staining
Immunocytochemistry was carried out using the SP kit
followed by the DAB Substrate Kit for Peroxidase
according to manufacturer’s instructions. Brieﬂy, the cells
were washed with PBS (pH 7.5) and incubated overnight at
4C with the primary antibodies. After washing three times
with PBS, the cells were incubated with a secondary anti-
body for 20 min at room temperature. After washing three
times with PBS, the cells were immunostained with avidin–
biotin complex for 30 min. Visualization of the immuno-
reactions was conducted with 3,30-diaminobenzidine (DAB,
Sigma, UK) for 5 min.
Western blot analysis
HepG2 cells were collected by centrifugation at 500 9 g
for 5 min, and the pellets were resuspended in lysis buffer
(1% NP40, 1 mM phenylmethylsulfonyl ﬂuoride, 40 mM
Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM NaOH) at 4
for 15 min. Cell lysates were fractionated on 12.5%
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nitrocellulose membrane according to standard protocols.
Antibody binding was detected by using the enhanced
chemiluminescence kit with hyper-ECL ﬁlm. The anti-
bodies against caspase3, caspase8, caspase9, DR5, Bcl-2,
Bax and b-actin were purchased from Santa Cruz Biotech
(Santa Cruz, CA, USA).
Statistical analysis
Values are shown as mean ± SEM. Statistical analysis was
done by Student’s t test and one-way ANOVA. P\0.05
was considered signiﬁcant. Statistical calculations were
performed by SPSS 13.0.
Results
Effects of delisheng on the proliferation and viability
of HepG2 and L-02 cell lines
Delisheng produced time and dose-dependent inhibition of
HepG2 cell growth and viability as compared to untreated
control cells (P\0.05). After 72 h of treatment with DLS,
the inhibitory ratio was low for treatment with 6.25 ll/ml
of DLS. The highest inhibitory ratio was about 87% for
cells treated with 100 ll/ml of DLS. The L-02 cells showed
much less sensitivity to delisheng compare with HepG2
cells (Table 1).
Cell cycle analysis
Flow cytometry data on cell cycle phase distribution
revealed that HepG2 cells treated with 25 ll/ml of DLS for
24 h exhibited 63.4, 26.9 and 9.6% of cells in G1, S and G2
phase of the cell cycle, respectively. Untreated HepG2 cells
exhibited 26.9, 57.8 and 15.3% of cells in G1, S and G2
phase of the cell cycle, respectively (Fig. 1). The DLS
(25 ll/ml) treated HepG2 cells showed arrest in the G1
phase of the cell cycle.
Annexin V-FITC/PI stained ﬂuorescence-activated cell
sorting study
By staining cells with Annexin V-FITC and PI, FACS was
used to distinguish and quantitatively determine the per-
centage of viable and apoptotic cells after treatment with
delisheng (6.25, 25, 100 ll/ml) at 24 h. Delisheng treat-
ment (6.25, 25, 100 ll/ml) induced apoptosis in 11.44,
21.86 and 29.67% of cells, respectively, as evidenced by
Annexin V positivity. Only 3.14% of untreated HepG2 cell
were Annexin V positive (Table 2; Fig. 2). Both control
and DLS-treated HepG2 cells showed hardly any evidence
of necrosis.
DLS triggers caspase-dependent apoptosis pathway
in HepG2 cells
To delineate the molecular events initiated by DLS, we ﬁrst
examined the requirement of caspases for the apoptotic
program. Exposure of HepG2 cells to DLS resulted in a
dose-dependent activation of caspase3, caspase9 and cas-
pase8 (Fig. 3a, b), which indicated the activation of both the
intrinsic and extrinsic apoptosis pathways. Moreover,
increases in expression levels of death receptor DR5
(Fig. 3b) conﬁrmed the activation of the extrinsic apoptosis
pathway. Mitochondria act as a point of integration for
apoptotic signals originating from both the extrinsic and
intrinsic apoptosis pathways [18]. Bcl-2 family members
Table 1 Growth inhibition
effects of delisheng on HepG2







Cells Concentration (ll/ml) Inhibition rate (%)
24 h 48 h 72 h
HepG2 6.25 12.19 ± 4.25
4 23.47 ± 5.25
4 30.96 ± 7.29
4
25.00 21.26 ± 7.06
q 38.14 ± 10.31
q 49.19 ± 9.23
q
100.00 55.13 ± 8.68
5 69.64 ± 9.25
5 87.57 ± 5.66
5
L-02 6.25 7.09 ± 3.47
m 10.13 ± 4.13
m 11.21 ± 2.58
m
25.00 14.37 ± 6.21
w 17.68 ± 8.45
w 18.75 ± 6.57
w
100.00 18.43 ± 5.32
. 19.65 ± 6.17
. 19.03 ± 4.89
.
Fig. 1 Effect of delisheng on the cell cycle phase distribution of
HepG2 cells. The experiments were repeated four times, the mean
percentage cells in G1, S and G2 phases of cell cycle were
represented. Error bars represent SEM (4 vs. * P\0.05)
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permeability [19]. Therefore, we examined the effects of
DLS on the expression levels of Bcl-2 family members in
HepG2 cells by western blotting. As shown in Figs. 3a and
4, DLS signiﬁcantly suppressed the expression level of Bcl-
2, and increased the expression level of Bax. These results
indicate that mitochondrial-mediated apoptosis in HepG2
cells, triggered by DLS, is predominantly associated with
down-regulation of the Bcl-2/Bax expression ratio.
Discussion
There are many in TCMs that have been used clinically for
[5,000 years in China and Asia, and increasing attention
is being paid to their scientiﬁc evaluation. Delisheng is a
common Chinese medicinal compound, whose effects have
been reported in patients with late-stage HCC. Speciﬁcally,
DLS has been reported to improve clinical symptoms and
quality of life, without severe adverse reactions. However,
the mechanisms responsible for these effects are unknown.
It is now well established that the reduced capacity of
tumor cells to undergo cell death through apoptosis, plays a
key role in both the pathogenesis of cancer and the failure of
current therapeutic treatments [20]. In the present study,
DLS strongly suppressed the proliferation and viability of
HepG2 cells, but only slightly inhibited proliferation and
viability of L-02 cells. Flow cytometric analysis showed
that DLS could induce apoptosis of HepG2 cells. The
antiproliferative effect of DLS can be attributed to cell cycle
arrest that is induced by the ability of DLS to halt the cell
cycle at the G1 phase to prevent further cell proliferation
and initiation of apoptotic signaling. DLS can suppress the
proliferation and induce apoptosis of HepG2 cells, but has
little effect on L-02 cells. This shows that DLS may possess
less toxicity for normal liver cells. The fact that DLS has
opposite effects on tumor cells and normal cells is intrigu-
ing. The results showed that treatment of liver cells with
DLS at concentrations\25 ll/ml is safe, but treatment at a
concentration of 100 ll/ml induces the same rate of apop-
tosis in liver cells as treatments with 25 ll/ml while
increases the effectiveness on HepG2 cells largely, which
suggests that higher concentrations of DLS can be used
when combined with liver protective agents.
Mitochondria act as a point of integration for apop-
totic signals because both the intrinsic and extrinsic path-
ways can converge to trigger mitochondrial membrane
Table 2 Apoptosis induction
effects of delisheng on HepG2
and L-02 cell lines
w vs
. P\0.05
4 Annexin V(?)/PI(-) cells
Cells Early apoptisis rate
4 (%)
Control DLS (6.25 ll/ml) DLS (25 ll/ml) DLS (100 ll/ml)
HepG2 3.14 ± 0.98 11.44 ± 3.14
w 21.86 ± 4.28
w 29.67 ± 3.01
w
L-02 2.03 ± 1.01 4.77 ± 1.25
. 8.96 ± 2.21
. 9.21 ± 1.98
.
Fig. 2 Effect of DLS on the Annexin V/PI binding of HepG2 and L-
02 cells. The experiments were repeated four times, the mean
percentage of apoptosis cells are represented. Error bars represent
SEM (5 vs. * P\0.05, * vs. *
? P\0.05)
Fig. 3 Western blot analysis of the expression levels of caspase3,
caspase9, Bcl-2, Bax, caspase8 and DR5 with the treatment of DLS
for 24 h (All the experiments were repeated four times.)
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both proapoptotic proteins, such as Bax, Bad and Bid, and
antiapoptotic proteins, such as Bcl-2 and Bcl-xL, tightly
regulate the mitochondrial apoptosis pathway. Many anti-
cancer drugs trigger mitochondria-mediated apoptosis in
cancer cells through downregulation of Bcl-2/Bcl-xL and/
or upregulation of Bax/Bad/Bid. Our results show that DLS
treatment signiﬁcantly downregulates Bcl-2 expression. In
our study, the expressions of Bax proteins were enhanced
greatly by DLS in a dose-dependent manner. Since Bax has
the ability to heterodimerize with the Bcl-2 protein, the
ratio of Bcl-2 to Bax appears to be an important marker for
the occurrence of apoptosis [22]. A higher Bcl-2/Bax ratio
confers a very poor prognosis with decreased rates of
complete remission and overall survival [23–26]. Thus,
down-regulation of the Bcl-2/Bax expression ratio could be
a predominant mechanism by which DLS induces mito-
chondria-mediated apoptosis in HepG2 cells.
Caspases, a family of cysteine acid proteases, are known
to act as important mediators of apoptosis. They are
induced by different stimuli and contribute to the overall
apoptotic phenotype by cleaving various cellular substrates
[27–29]. Tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL), also known as Apo2L, is a
cytokine of the TNF family which is capable of inducing
apoptotic cell death in a variety of cancer cell types, while
having only negligible effects on normal cells [30–32].
DR5 contains a conserved cytoplasmic domain called the
‘death domain’ that is required for TRAIL-induced apop-
tosis [33–35]. We found that DLS treatment upregulated
the expression of death receptor DR5. Activation of
caspase-8 is required for death receptor-induced apoptosis
[36, 37].Correspondingly, the reduction of Procaspase3, 8
and 9 in DLS-treated HepG2 cells could indicate that the
caspases were activated since the activation of caspase
activity results from cleavage of procaspases. For example,
activated caspase8 can cleave and activate effector
caspase-3. On the other hand, caspase-8 can induce Bid
cleavage. The cleaved Bid causes the cytochrome c efﬂux
from mitochondria, then activation of caspase9 and 3 [38].
All of this evidence shows that both the extrinsic and the
intrinsic signaling pathways contribute to the DLS-induced
apoptosis of HepG2 cells.
In summary, our results suggest that DLS inhibits the
growth of HepG2 cells through induction of caspase-
mediated apoptosis. Both the extrinsic and intrinsic sig-
naling pathways contribute to DLS-induced apoptosis.
Further elucidation of the mechanisms involved in the
activity of delisheng will help in the development of new
approaches to therapy of HCC and other cancers.
Fig. 4 Bcl-2, Bax, DR5 protein
expression in HepG2 cells
(9200). a, c, e
Immunocytochemistry of Bcl-2,
Bax and DR5 staining in HepG2
cells for 24 h of treatment
without DLS. b, d, f
Immunocytochemistry of Bcl-2,
Bax and DR5 staining in HepG2
cells for 24 h of treatment with
25 ll/ml DLS (All the
experiments were repeated four
times.)
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